VL 2397

Drug Profile

VL 2397

Alternative Names: ASP-2397; VL-2397

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Vical
  • Class Anti-infectives; Antifungals; Macrocyclic compounds
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aspergillosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Aspergillosis

Most Recent Events

  • 20 Feb 2018 Phase-II clinical trials in Aspergillosis (In volunteers) in Asia, Europe and North America (IV) (NCT03327727)
  • 01 Feb 2018 Vical and the Mycoses Study Group Education and Research Consortium (MSGERC) collaborate for clinical development of VL 2397 for Invasive aspergillosis
  • 30 Jan 2018 Vical plans a phase II trial for invasive Aspergillosis in Q1 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top